Neil Aronin MD
Diabetes, Lipid Metabolism, Pituitary Disorders & Neuroendocrinology
Professor of Medicine, University Mass School of Medicine
Join to View Full Profile
55 Lake Ave NDepartment Of EndocrinologyWorcester, MA 01655
Phone+1 508-856-3536
Dr. Aronin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 1979 - 1982
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalFellowship, Endocrinology, Diabetes, and Metabolism, 1978 - 1979- Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1977 - 1978
Duke University HospitalResidency, Internal Medicine, 1974 - 1977
Perelman School of Medicine at the University of PennsylvaniaClass of 1974
Certifications & Licensure
MA State Medical License 1980 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Meaningful Use Advisor, MedCPU Inc., 2011, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2011, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise E HR Modular, Allscripts, 2011, 2013-2014, 2016-2017
Publications & Presentations
PubMed
- ESC derived human cortical neurons harboring the NACC1 c.892C > T p.R298W missense mutation exhibit molecular differences from controls that influence neuronal maturat...Mark Deehan, Ellen Sapp, Andrew Iwanowicz, Josine Kothuis, Elizabeth Weisman
Human Molecular Genetics. 2025-10-14 - Intrastriatal Delivery of a Zinc Finger Protein Targeting the Mutant HTT Gene Allele Obviates Lipid Phenotypes in Brain and Plasma in Huntington's Disease Mice.Andrew Iwanowicz, Adel Boudi, Connor Seeley, Ellen Sapp, Rachael Miller
Human Gene Therapy. 2025-08-01 - Blocking somatic repeat expansion and lowering huntingtin via RNA interference synergize to prevent Huntington's disease pathogenesis in mice.Jillian Belgrad, Ashley Summers, Christian Landles, Jonathan R Greene, Samuel Hildebrand
Biorxiv. 2025-06-25
Journal Articles
- A Fresh Look at Huntingtin mRNA Processing in Huntington’s DiseaseNeil Aronin, MD, Journal of Pediatric Rehabilitation Medicine
Press Mentions
Atalanta Therapeutics Strengthens Leadership Team with Key Appointments in R&D and Corporate DevelopmentOctober 7th, 2021- Atalanta Therapeutics Launches to Develop RNAi Therapies for Neurodegenerative DiseasesJanuary 14th, 2021
- RNAi Biotech Atalanta Debuts with $110m plus Biogen and Roche CNS Tie-UpsJanuary 12th, 2021
Grant Support
- Advancing RNA Therapeutics for Huntington’s DiseaseUNIV OF MASSACHUSETTS MED SCH WORCESTER2020–2025
- Signaling Mechanisms In Neuronal DegenerationNational Institute Of Neurological Disorders And Stroke1999–2012
- Interdisciplinary Studies In Hormone FunctionNational Institute Of Diabetes And Digestive And Kidney Diseases2008–2011
- Receptor Mechanisms In Movement Disorder PathophysiologyNational Institute Of Neurological Disorders And Stroke1996–1998
- Hypothalamic Anterior Pituitary RelationshipsNational Institute Of Diabetes And Digestive And Kidney Diseases1986
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
